May 14, 2020 / 12:29 PM / 19 days ago

BRIEF-Magenta Therapeutics Presents Data Demonstrating Cells Mobilized With MGTA-145 In A Phase I Trial Are Effective In Gene Therapy Settings

May 14 (Reuters) - Magenta Therapeutics Inc:

* MAGENTA THERAPEUTICS PRESENTS DATA AT ANNUAL MEETING OF AMERICAN SOCIETY OF GENE AND CELL THERAPY DEMONSTRATING CELLS MOBILIZED WITH MGTA-145 IN A PHASE I TRIAL ARE EFFECTIVE IN GENE THERAPY SETTINGS

* MAGENTA THERAPEUTICS - MGTA-145 WAS SHOWN TO BE RAPID, RELIABLE, EFFICIENT AND G-CSF-FREE METHOD TO OBTAIN HIGH NUMBERS OF FUNCTIONAL HSCS IN PHASE 1 TRIAL

* MAGENTA THERAPEUTICS - ADDITIONAL PRECLINICAL DATA SHOW MGTA-145 SERVES AS EFFICIENT, SAME-DAY MOBILIZATION REGIMEN FOR IN VIVO HSC GENE THERAPY IN ANIMALS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below